Acinetobacter infections and antibiotic resistance at Pepe Portilla Pediatric Hospital Pinar del Rio, Pinar del Rio province
Keywords:
ACINETOBACTER, ACINETOBACTER INFECTIONS, HOSPITALS, PEDIATRIC, ANTI-INFECTIVE AGENTS, MICROBIOLOGY, PEDIATRICS.Abstract
Introduction: Acinetobacter spp. infections are a health problem because they are a growing cause of infections in intensive care and oncohematological services.
Objective: to determine infections and antibiotic resistance by Acinetobacter spp at Pepe Portilla Pediatric Hospital during 2019 and 2020.
Methods: a cross-sectional, descriptive, observational, research-development study was conducted; the target group and the sample comprised 26 patients with Acinetobacter infection, the documentary review was the source of information, analyzing blood cultures, cerebrospinal fluid, endotracheal secretions, pleural probe and venous catheter cultures.
Results: twenty-six Acinetobacter strains were isolated, 88,5 % corresponded to the Acinetobacter calcoaceticus-baumannii (Acb) complex, predominating in intensive care 42,3 %, respiratory and miscellaneous services 19,2 % and 15,4 % respectively; non-Acb strains represented 11,5 %. There was absolute resistance to ampicillin, 92,3 %, cefazolin 76,9 %, cefuroxime, with resistance to the rest of the third and fourth generation cephalosporins ranging from 46.1 % to 53.8 %; 30.8 % showed a multidrug-resistant pattern, 57,7 % extremely multidrug-resistant of the Acb complex; 73,1 % were positive for the presence of a carbapenemase, of which 69,2 % of the Acb complex. Children under 5 years of age 69,6 %, previous use of antimicrobials 56,6 %, use of venous catheter 43,5 %, were the most common risk factors found.
Conclusions: Acinetobacter infections are a cause of serious morbidity in patients at risk.
Downloads
References
1. Ortega González LM, Duque Vizcaíno M, Valdés Casanova J, Verdasquera Corcho D. Sepsis grave en la unidad de terapia intensiva del Instituto de Medicina Tropical “Pedro Kourí”. Rev Cubana Salud Pública [Internet]. 2018 Jun [Citado: 04/10/2020]; 44(2): 213-223. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662018000200213&lng=es .
2. Rada Cuentas J. Acinetobacter un patógeno actual. Rev. bol. ped. [Internet]. 2016 [Citado: 04/10/2020]; 55(1): 29-48. Disponible en: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1024-06752016000100006&lng=es
3. Villanueva X, Opazo Capurro A, Quezada Aguiluz M, Domínguez M, BelloTH, González Rocha G. ¿Se debe revisar la determinación de la CIM de colistín en Acinetobacterbaumannii?. Rev. chil. infectol. [Internet]. 2017 Ago [Citado: 04/10/2020]; 34(4): 413-414. Disponible en: http://dx.doi.org/10.4067/s0716-10182017000400413.
4. Pérez Quintero CP, González Ruiz G, Pertuz Meza Y, Carrasquilla D. Carga y tipología microbiana relacionada con infecciones asociadas a la asistencia sanitaria en servicios clínicos. Rev Cuba Enferm [Internet]. 2019 [Citado: 04/10/2020]; 34(4): Disponible en: http://revenfermeria.sld.cu/index.php/enf/article/view/1643
5. Monté Cerero L, Martínez Casanueva R. Microorganismos aislados en pacientes ingresados. Hospital "Salvador Allende", La Habana. Febrero a junio de 2015. Revhabanciencméd [Internet]. 2017 Ago [Citado: 04/10/2020]; 16(4): 552-563. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2017000400007&lng=es.
6. Pérez Verea L, Fernández Ferrer A, Díaz Hernández D, González Volte R, Fernandez Tamayo P. Gérmenes aislados en pacientes ingresados en la terapia intensiva del Hospital Clínico Quirúrgico Provincial “Dr. Joaquín Albarrán”. Rev Cubana InvBioméd [Internet]. 2020 [Citado: 04/10/2020]; 39(3): e612. Disponible en: http://scielo.sld.cu/pdf/ibi/v39n3/1561-3011-ibi-39-03-e612.pdf
7. Escalona Y, Guedez, Z, Silva J. Hemocultivos en pacientes hospitalizados en la Ciudad Hospitalaria “Dr. Enrique Tejera”. Salud [Internet]. 2017 [Citado: 04/10/2020]; 21(3): 24-30. Disponible en: http://www.redalyc.org/articulo.oa?id=375955679006
8. Procop G, church D, et al. Koneman´s Color Atlas and Textbook of Diagnotic Microbiology. 7a. ed..S/I. Lippincott Williams and Wilkins [Internet]. 2017 [Citado: 04/10/2020]: p.609-11. Disponible en: https://scholar.google.com.cu/scholar?q=Koneman%27s+Color+Atlas+and+Textbook+of+Diagnostic+Microbiology.+7a.+ed.&hl=es&as_sdt=0&as_vis=1&oi=scholart
9. Gutiérrez MJ, Morayta RCA, Martínez BME, et al. Estudio multicéntrico de resistencias bacterianas nosocomiales en México. RevLatinInfectPediatr[Internet]. 2017 [Citado: 04/10/2020]; 30(2): 68-75. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=74667
10. Salazar Holguín HD, Cisneros Robledo ME. Antibibiotic resistance by nosocomial infections’ causal agents. Rev Med Inst Mex Seguro Soc[Internet]. 2016 [Citado: 04/10/2020]; 54(4): 462-471.
Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDREVISTA=46&IDARTICULO=66932&IDPUBLICACION=6557
11. Rivero Monrey RJ. Resistencia antimicrobiana en Unidades de Cuidados Intensivos. Rev16 de Abril [Internet]. 2019 [Citado: 04/10/2020]; 58(274): 119-125. Disponible en: <http://www.rev16deabril.sld.cu/index.php/16_04/article/view/831>.
12. Barletta Farías RC, Pérez Ponce LJ, Barletta del Castillo JE, González Guirola MA, Sánchez Castellanos RL, Pujol Pérez M. Caracterización clínica y microbiológica de pacientes con neumonía asociada a la ventilación mecánica, Cienfuegos 2015-2017. Medisur [Internet]. 2019 Ago [Citado: 04/10/2020]; 17(4): 514-524. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2019000400514&lng=es.
13. Angles Yanqui E, Chumbes Pérez J, Huaringa Marcelo J. Colistina en el tratamiento de infecciones por pseudomonas aeruginosa y acinetobacter baumannii extensivamente resistentes (XDR) en un hospital de tercer nivel. Infectio. [Internet]. 2020 [Citado: 11/11/2020]; 24(4): 201-207. Disponible en: http://dx.doi.org/10.22354/in.v24i4.876.
14. Campo Deglmann R, Oliveira D, Candeixa de Franca PH. Perfil fenotípico de resistencia a la colistina y tigeciclina en un hospital público de Brasil. Journal of Epidemiology and Infection Control [Internet]. 2019 Oct [Citado: 11/11/2020]; 9(4): 1-6. Disponible en: https://online.unisc.br/seer/index.php/epidemiologia/article/view/13345
15. Hernández Gómez CH, Hercilla L, Mendo F, Pérez Lazo G, Contreras E, Ramírez E, et al.Antimicrobial Stewardship programs in Peru: A fundamental agreement. Rev. chil. infectol [Internet]. 2019 Oct [Citado: 11/11/2020]; 36(5): 565-575. Disponible en: http://dx.doi.org/10.4067/S0716-10182019000500565.
16. Velázquez Acosta C, Cornejo Juárez P, Volkow Fernández P. Cepas E-ESKAPE multidrogorresistentes aisladas en hemocultivos de pacientes con cáncer. salud publica mex [Internet]. 2018 [Citado: 11/11/2020]; 60(2): 151-157.Disponible en:
https://www.medigraphic.com/cgiin/new/resumenI.cgi?IDREVISTA=79&IDARTICULO=78459&IDPUBLICACION=7586
17. Ramette A, Kronenberg A, Burnens A. Prevalence of carbapenem-resistant Acinetobacterbaumannii from 2005 to 2016 in Switzerland. BMC Infect Dis [Internet]. 2018 [Citado: 11/11/2020]; 18: 1-6. Disponible en: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3061-5
18. Varón FA. Mortalidad y desenlaces clínicos en pacientes críticamente enfermos con infecciones por bacterias productoras de carbapenemasas en un hospital de alta complejidad en Bogotá, Colombia. Infectio [Internet]. 2021 [Citado: 11/11/2020]; 25(1): 16-21. Disponible en: http://revistainfectio.org/index.php/infectio/article/view/903/1001
19. Pérez Farias YC, Pérez Quiñones D, Carmona Cartaya Y. Complejo Acinetobacter baumannii- calcoaceticus multidrogor resistente productor de Betalactamasas en hospitales cubanos.IPK, 2016. Convención Internacional de Salud, Cuba Salud [Internet]. 2018 [Citado: 11/11/2020: 1-8. Disponible en:
http://www.convencionsalud2017.sld.cu/index.php/connvencionsalud/2018/paper/view/1958/790
20. – Angles Yanqui E, Huaringa Marcelo J, Sacsaquispe Contreras R, Pampa Espinoza L. Panorama de las carbapenemasas en Perú. Rev Panam Salud Pública [Internet]. 2020 [Citado: 11/11/2020]; 44: e61. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/52327/v44e612020.pdf?sequence=1&isAllowed=y
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/